Regeneron Pharmaceuticals Inc. buy phonebroker
Summary
This prediction ended on 20.07.15 with a price of €513.50. The BUY prediction by phonebroker finished with a performance of 11.97%. phonebroker has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -2.598% | -2.598% | 32.775% | 87.318% |
iShares Core DAX® | -1.611% | 3.135% | 15.880% | 15.652% |
iShares Nasdaq 100 | -0.500% | 0.775% | 20.054% | 32.402% |
iShares Nikkei 225® | -1.483% | 4.610% | 11.154% | -1.568% |
iShares S&P 500 | -0.501% | 1.914% | 21.016% | 37.314% |
Comments by phonebroker for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Spekulativ kaufen
Gute Nachrichtenlage, schöne Kursentwicklung.